Table 4.
Summary of studies related to sofosbuvir-based regimens in patients with severe renal impairment including cohorts with HCV GT2-infected patients
| Regimens (%) | GT (%) | SVR12, % | No. of HD | SVR12 or SVR24 in HD Pts | AEs in HD Pts | Reference |
|---|---|---|---|---|---|---|
| SOF/SMV (17) | 1 (90) | 83 | 12 | GT1 81.8% | Anemia | Desnoyer et al. (2016) [15] |
| SOF/LDV (8) | 2 (10) | |||||
| SOF/DCV (33) | ||||||
| SOF TIW/DCV (33) | ||||||
| SOF TIW/RBV (8) | ||||||
| SOF/PEG/RBV (18) | 1 (72) | 88 | 5 | 100% | Anemia | Saxena et al. (2016) [18] |
| SOF/RBV (30) | 2 (16) | GT is not available | ||||
| SOF/SMV (40) | 3 (9) | |||||
| SOF/SMV/RBV (11) | Other (3) | |||||
| SOF/LDV (62) | 1 (72) | 97 | 20 | 95% | Anemia | Cox-North et al. (2017) [19] |
| SOF/LDV/RBV (7) | 2 (7) | GT is not available | ||||
| SOF/DCV (21) | 3 (17) | |||||
| SOF/DCV/RBV (3) | Other (4) | |||||
| SOF/RBV (7) | ||||||
| SOF/RBV (63) | 1 (65) | 95.2 | 62 | GT1 97.5% | Anemia | Agarwal et al. (2017)[20] |
| SOF AD/RBV (3) | 2 (2) | GT3 94.4% | Dyspepsia | |||
| SOF/DCV (10) | 3 (29) | |||||
| SOF AD/RBV (24) | Other (4) |
HCV, hepatitis C virus; GT, genotype; SVR, sustained virological response; HD, hemodialysis; Pts, patients; AE, adverse event; SOF, sofosbuvir; SMV, simeprevir; LDV, ledipasvir; DCV, daclatasvir; TIW, three times a week; RBV, ribavirin; PEG, pegylated interferon; AD, alternate day.